UniDevice : Q1 2021 – quarterly report

Q1 Report of UniDevice AG

IFRS consolidation

March 31, 2021

Commercial register:	Berlin-Charlottenburg
Commercial register number:	HRB 190230 B

The share

Nominal capital	15,050,000.00 EUR
Classes of shares	Bearer shares
WKN / ISIN	A11QLU / DE000A11QLU3
Number of shares	15,050,000
Stock symbol	UDC
Listing	Munich stock exchange	Frankfurt stock exchange
Stock market segment	m:access	Open Market
First trading day	March 06, 2018	March 07, 2018
Designated Sponsor,
Listing Partner, Specialist	mwb fairtrade Wertpapierhandelsbank AG

The bond

Nominal amount	up to 20,000,000.00 EUR
Interest coupon	6.5%
Bond class	Owner bond
WKN / ISIN	A254PV / DE000A254PV7
Listing	Frankfurt stock exchange
First trading day	December 17, 2019
Specialist	Wolfgang Steubing AG Wertpapierhandelsbank

Content	Page
Letter to the shareholders	1
Group Management Report	3
IFRS Consolidated Financials	8
Notes to the consolidated financials	12

Letter to the shareholders

Dear shareholders, dear Sirs and Madames,

the international B2B brokerage for communication technology with a focus on high-priced smartphones from leading manufacturers such as Apple and Samsung was successful in the first quarter of 2021. The profit rose by 24.9% compared to the same period in the previous year to EUR 923 thousand. The sale of Apple AirPods was particularly successful. Since the unit prices for these products are lower than those of Apple iPhones, sales fell by 9.6% compared to the same period last year to EUR 92,090 thousand, despite high unit sales and an increase in profit.

The corona pandemic had a negative impact on SaniSolutions GmbH (a specialty medical center for state-of-the-art rehabilitation technology with three locations nationwide). Visiting restrictions and bans apply, which severely limit the possibilities of providing care services.

Sales fell by 39.7% compared to the same period in the previous year to EUR 519 thousand. The loss for the period was EUR -75 thousand.

In the medical technology sector, as in other areas, regulations are constantly being tightened by the legislature. For SaniSolutions GmbH, regulatory tightening by the MDR (EU Medical Device Regulation) is relevant.

Due to the implementation and certification of ISO 13485 as well as the creation of the technical documentation and the risk analyzes according to the new MDR specifications, SaniSo- lutions GmbH is one of the still very small number of specialist suppliers who already meet the regulations of the new MDR that will apply from May 2021 and thus are future-proof.

In total, sales of EUR 92,609 thousand (-9.8% compared to the same period of the previous year) were achieved in the first quarter of 2021 with a period surplus of EUR 848 thousand (+ 20.2% compared to the same period in the previous year).

We are optimistic about the further course of the 2021 financial year.

I will therefore propose a dividend of 12 cents per share on the part of the board of directors for the general meeting (so far it remains the planned date on June 28, 2021 in Berlin).

1

At this point I can once again thank the employees for their high level of commitment, especially in this difficult time of the corona pandemic.

I would like to thank the members of the Supervisory Board for the good cooperation.

Dr. Christian Pahl

(CEO)

April 2021

2

Group Management Report

March 31, 2021

1. Basis of the group

1. Economic report

1. Events after the balance sheet date IV. Outlook

1. Risk report

3